A novel approach to target inflammatory diseases

A novel approach to target inflammatory diseases

frenchtech-wht

Inotrem is an advanced clinical stage biotechnology company specialized in immunotherapy. The company has developed a new concept of immunomodulation that targets TREM-1, to control unbalanced and dysregulated inflammatory responses.

More about Inotrem
Inotrem_Picto Trem 1

Inotrem targets the TREM-1 pathway as a key factor in unbalanced inflammatory responses. The company focuses on the therapeutic and diagnostic tools derived from its knowledge of the biology of the TREM-1 pathway.

More about our Therapeutic Approach
Inotrem_Picto Pipeline

Inotrem has 2 late-stage clinical programs ongoing in acute inflammatory diseases such as septic shock and COVID-19 with its lead product nangibotide. Inotrem also targets chronic inflammatory diseases through a broad anti-TREM monoclonal antibody program.

More about Drug development
Inotrem_Picto Trem 1

Inotrem targets the TREM-1 pathway as a key factor in unbalanced inflammatory responses. The company focuses on the therapeutic and diagnostic tools derived from its knowledge of the biology of the TREM-1 pathway

More about our Therapeutic Approach
Inotrem_Picto Pipeline

Inotrem has 2 late-stage clinical programs ongoing in acute inflammatory diseases such as septic shock and COVID-19 with its lead product nangibotide. Inotrem also targets chronic inflammatory diseases through a broad anti-TREM monoclonal antibody program.

More about Drug development
See all news & events
See all news & events

Sven Zimmermann, CEO, presents Inotrem’s technology, programs and outlook